82 results about "Glucuronide" patented technology

The present invention belongs to the field of biotechnology, and specifically relates to a GmSGT2 gene related to plant height and branch development, and a mutant thereof and the use thereof. A Glycine max mutant having fewer branches and decreased plant height is obtained by means of EMS mutagenesis, and a target gene thereof that is located by means of a map-based cloning technique is a GmSGT2 gene of Hedou 12. It is found through searching that the gene encodes soyasapogenol B glucuronide galactosyltransferase, and can galactosylate soyasapogenol B monoglucuronide, thereby affecting the plant height of Glycine max and reducing the branches of Glycine max. Therefore, the GmSGT2 mutant can be used for cultivating dwarf high-yield Glycine max varieties, and is of great significance in the breeding of ideal plant types of Glycine max and research on important agronomic traits of plants. The mutant has broad application prospects and great research value with regard to understanding the plant height and branch regulation mechanism of Glycine max and improving the process of Glycine max breeding; and can provide an excellent germplasm resource stock for regulating the close planting and high-yield breeding of Glycine max.

The specification relates to conjugates comprising a linker of Formula (IA):and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.

This disclosure presents describes methods for the chemical glycosylation and glucuronidation of cannabinoids. These methods use readily available glycosyl and glucuronyl donors and offer a convenient and versatile approach to access a diverse range of cannabinoid glycosides and glucuronides. Selected compounds have been evaluated for their physicochemical properties and in vitro stability to understand the structure-property relationship and identify their potential applications. The possible uses of these compounds could span various fields, including medicine, consumer goods, and nutrition supplements.

The application discloses application of total flavones of chrysanthemum morifolium ramat and metabolites thereof in preparation of uric acid-lowering or liver and kidney protecting drugs or health care products. The total flavones of chrysanthemum morifolium ramat contain various flavone compounds. In a hyperuricemia model mouse, the total flavones of chrysanthemum morifolium ramat can significantly reduce blood uric acid level, and has a significant protective effect on liver and kidney, and the effect is achieved by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver, and regulating the expression of uric acid related transporters in the kidney. Meanwhile, metabolites of the total flavones of chrysanthemum morifolium ramat, luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, can also play a pharmacological role in the mouse body. In vitro experiments and mouse primary hepatocytes further prove that luteolin-7-O-glucuronide and apigenin-7-O-glucuronide have an inhibiting effect on the activity and expression level of xanthine oxidase. The application widens the application range of traditional Chinese medicinal materials, and provides a new direction for development of efficient and low-toxic uric acid-lowering and anti-gout drugs or health care products.

The invention provides a method for extracting acacetin-7-O-glucuronide from dracocephalum moldavica, and relates to the technical field of medicine extraction. The method comprises the following steps: heating and extracting dracocephalum moldavica or dracocephalum moldavica products by adopting an alkaline solution, and precipitating the obtained extracting solution under the condition that the pH value is 1-3 to obtain a precipitate extract; mixing n-hexane, ethyl acetate, ethanol and water, and layering to obtain an upper phase solution and a lower phase solution; and dissolving the precipitate extract with a lower-phase solution, carrying out high-speed counter-current chromatography separation on the obtained sample solution, and collecting an acacetin-7-O-glucuronide fraction according to a chromatogram. According to the method, alkali extraction, acid precipitation and high-speed counter-current chromatography are combined, process conditions are optimized, the high-purity monomer of acacetin-7-O-glucuronide in dracocephalum moldavica is rapidly prepared, and the process is simple.

The invention relates to a traditional Chinese medicine composition which comprises more than 1.09 permillage of ephedrine hydrochloride, more than 0.86 permillage of pseudoephedrine hydrochloride, more than 0.17 permillage of peiminine, more than 0.03 permillage of peimine, more than 0.17 permillage of chrysin-7-O-glucuronide, more than 0.002 permillage of glycyrrhetinic acid, more than 11.87 permillage of amygdalin and more than 0.01 permillage of neotuberostemonine. The oral liquid is prepared from more than 2.16 per mill of glycyrrhizic acid, more than 1.97 per mill of oroxylin A, more than 1.97 per mill of oroxylin B, more than 1.23 per mill of liquiritin, more than 0.59 per mill of apiose liquiritin, more than 0.55 per mill of baicalin, more than 0.23 per mill of chlorogenic acid, more than 0.18 per mill of praeruptorin A, more than 0.15 per mill of wild melanosin, more than 0.14 per mill of methyephedrine hydrochloride, more than 0.13 per mill of isoliquiritin, more than 0.13 per mill of neochlorogenic acid and more than 0.13 per mill of cryptochlorogenic acid. The composition is prepared from more than 0.10% of peimine, more than 0.08% of baicalein, more than 0.05% of praeruptorin B, more than 0.04% of praeruptorin C, more than 0.011% of xanthoxylin and more than 0.0006% of formononetin.

The invention relates to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating urolithiasis and preparation and application thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials and monomers in parts by weight: 10 to 30 parts of endothelium corneum gigeriae galli, 10 to 30 parts of rhizoma phragmitis, 10 to 30 parts of poria cocos, 10 to 20 parts of radix angelicae sinensis, 10 to 20 parts of herba cistanche, 10 to 20 parts of herba cepbalanoplosis segeti, 10 to 15 parts of fructus gardeniae, 5 to 10 parts of liquorice root and 1 to 6 parts of gossypotin 8-O-glucuronide. According to the traditional Chinese medicine theory of clearing heat, treating stranguria, dissolving stone and strengthening body resistance, modern pharmacological research is combined, scientific compatibility is carried out through chemical cutting, the synergistic effects of clearing heat, cooling blood, inducing diuresis, treating stranguria, dissolving stone, relieving pain, tonifying kidney and strengthening body resistance are achieved, the preparation process is efficient and controllable, and clinical application is safe and effective.

The present invention discloses a method for constructing a fingerprint of Gualou Niu Bang decoction, relating to the technical field of analytical chemistry. The method is simple and has high precision, stability, and repeatability. Determination revealed that seven components, including geniposide, liquiritin, hesperidin, arctiin, baicalin, melaleucalyptol A-7-O-β-D-glucuronide, and wogonin, can be used as common characteristic peaks in the fingerprint of Gualou Niu Bang decoction for identification research.

The invention relates to the technical field of pharmaceutical analysis, and discloses a method for simultaneously determining the contents of various components in Shuanling antidiarrheal granules based on a UPLC-QQQ-MS / MS. The contents of 18 components in the Shuanling antidiarrheal granules are simultaneously determined by using an ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometer. The 18 components comprise adenosine, gallic acid, protocatechuic acid, neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, liquiritin, ellagic acid, kaempferitrin, narirutin, hesperidin, baicalin, oroxylin A-7-O-beta-D-glucuronide, wogonin, baicalein, wogonin, pachymic acid B and pachymic acid A. The invention further discloses a preparation method of the pharmaceutical composition. Through the UPLC-QTRAP-MS / MS combined technology, the technical prejudice that single component depends on in quality control of the traditional Chinese medicine compound preparation is broken through, the key problems that multiple components in a complex matrix are difficult to separate, low-content components are difficult to detect and the like are solved, efficient, accurate and synchronous determination of 18 components is achieved, and the method is suitable for large-scale popularization and application. A new reference path is opened up for modernized quality control of the traditional Chinese medicine compound preparation.

The invention discloses a preparation method and application of a quercetin derivative grafted with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione with a blood sugar reducing function. According to the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound disclosed by the invention, the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is prepared by linking quercetin-3-O-glucuronide with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione, the structural formula of the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is shown as a formula (I), and the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound prepared by the invention has the function of reducing blood sugar and can be used for preparing medicines for treating diabetes mellitus.

The invention discloses an intestinal tract hemostatic composition as well as a preparation method and application thereof, and relates to the field of hemostatic drugs. Wherein the catechin, the hyperoside, the isoquercitrin, the quercetin-3-O-glucuronide, the gallocatechin, the myricetin-3-O-galactoside, the proanthocyanidin B1, the proanthocyanidin B3, the syringe-3-O-glucoside and the astragalus smicus glycoside are flavonoid compounds; nuciferine, higenamine, N-methyl-higenamine and N-trans-feruloyl tyramine are taken as alkaloid compounds, and the compound is selected from the group consisting of higenamine, nuciferine, higenamine The composition has the advantages of simple preparation process, good hemostatic effect and the like, and provides a new raw material choice for the development of intestinal bleeding treatment medicines.

The invention discloses a keloid treatment gel material capable of reducing lactic acid generation, and belongs to the technical field of keloid treatment. The material is prepared by the following steps: firstly, carrying out esterification on 9-oxabicyclo [3.3. 1] nonane-2, 6-diol and S-allyl-L-cysteine to obtain an intermediate A, and then carrying out Schiff base reaction on the intermediate A and 5-methoxy heliotropin to obtain an intermediate B containing double bonds; then, copolymerizing with methylacryloylated chitosan and polyethylene glycol diacrylate under photo-initiation to form a cross-linked network structure; finally, active ingredients such as quercetin-3-O-glucuronide and luteolin-3 '-glucuronide are included, and auxiliary materials such as a humectant and a preservative are added, so that the composition is prepared. The gel has a slow release function, can effectively inhibit glycolysis, reduce lactic acid generation, scavenge free radicals and regulate inflammation and fibrosis microenvironment, has good biocompatibility and oxidation response drug release characteristics, and is suitable for prevention and treatment of keloids.

This invention discloses a recombinant glucuronide C5 epimerase mutant, expression vector, recombinant expression engineered bacteria, and their culture and induction methods, belonging to the field of biotechnology. The recombinant enzyme sequence is formed by fusing a truncated (N29–N617) mutation (V173R–V197K–A239V–N269E) with an N-terminal maltose-binding protein (MBP) tag to a human glucuronide C5 epimerase (C5-epi). The recombinant glucuronide C5 epimerase mutant exhibits higher activity, 2.1 times that of the recombinant wild-type, and greater stability, retaining 72.5% of its activity after 5 days at room temperature. Furthermore, the soluble expression level of this recombinant mutant glucuronide C5 epimerase is increased by 4-fold.

The invention discloses application of C-phycocyanin and D-glucuronic acid in directly improving sperm motility in vitro and improving sperm motility after freezing recovery, and belongs to the technical field of biological medicine. According to the present invention, the mixed solution of D-glucuronic acid, C-phycocyanin, and D-phycocyanin has significant effects of in-vitro sperm motility promotion and sperm function protection, can be used for preparing the sperm motility improving drug or the sperm treatment reagent in the assisted reproduction technology, and has good application prospects.

The invention discloses an enzyme for metabolizing glyphosate as well as a gene promoter and application thereof. According to the invention, the glyphosate tolerant germplasm Kitaake is screened for the first time. Moreover, the glycosyl transferase gene GRGT1 (Os04g0206500) which plays a key role in improving the glyphosate tolerance is identified in Kitaake for the first time, and the gene expression level under the stress of glyphosate is remarkably improved due to deletion of a single base A at a site 803 in a promoter region of the glycosyl transferase gene GRGT1 (Os04g0206500). The GRGT1 protease can catalyze a glycosylation reaction between glyphosate and two glycosyl donors UDP-glucose and UDP-glucuronic acid to generate low-toxicity derivatives M331 and M345, so that the residue of glyphosate in rice is reduced. The invention systematically discloses a glyphosate-resistant glycosylation metabolism mechanism of rice, discovers a new glyphosate metabolism gene, and provides a basis for creating efficient resistant germplasm resources.

The invention discloses a preparation method of a pyronaphthyridine metabolite, which comprises the following steps: reacting a compound A serving as a raw material with a compound B (2, 3, 4-tri-O-acetyl-alpha-D-glucuronide methyl ester trichloroacetimidate) under the action of a catalyst to obtain a compound C, and hydrolyzing the compound C under an alkaline condition to obtain a compound D, namely the pyronaphthyridine metabolite. The preparation method disclosed by the invention is reasonable in design, simple in post-treatment, easily available in raw materials and high in operability; the purity of the prepared target product can reach 97.0% or above, the method can be used for pharmacokinetic research, a test sample is provided for research on the metabolic mechanism of the pyronaphthyridine, and the method has important application value.

A method for extracting flavonoid components in Dracocephalum moldavica L., comprising the following steps: mixing Dracocephalum moldavica L. and an alkaline solution for heating extraction; under the condition that the pH value is 1-3, mixing an obtained extract solution with acid for precipitation; dissolving an obtained precipitated extract and then carrying out preparative liquid chromatography separation; and respectively concentrating obtained Fr1-Fr6 fractions until the fractions are dry, so as to sequentially obtain luteolin-7-O-β-D-glucuronide, apigenin-7-O-β-D-glucuronide, diosmetin-7-O-β-D-glucuronide, tilianin, acacetin-7-O-glucuronide, and acacetin.

The present invention relates to a compound selected from nitazoxanide, tizoxanide, tizoxanide glucuronide and pharmaceutically acceptable salts thereof, for use in a method for the treatment of hepatic impairment.

The invention discloses an application of apigenin-7-O-beta-D-glucuronide in preparation of a medicine for treating fundus diseases, and establishes a model of ischemic fundus diseases of guinea pigs and a model of eyeball conjunctival microcirculation disturbance of rabbits. The prevention and treatment effects of the apigenin-7-O-beta-D-glucuronide on fundus diseases and fundus lesions are researched, and an experimental basis is provided for clinical treatment of the fundus diseases by the apigenin-7-O-beta-D-glucuronide.

The invention belongs to the crossing field of traditional Chinese medicine modernization and biotechnology, and particularly relates to application of a metabolic marker in preparation of a product for auxiliary diagnosis of retinal vein occlusion (RVO) or evaluation of prognosis of treatment of RVO by ginseng-wolfberry omentum granules. The metabolic marker is selected from at least one of the following metabolites: leukotriene B4, (R)-2-feruloyl-1-(4-hydroxyphenyl)-1, 2-ethylene glycol, hyoscyamine base A6, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxy-5, 6, 7, 8, 9, 10, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxyl-5, 6, 7, 8, 10-tetrahydroxyl-5, 7, 8, 10 The invention relates to an anti-inflammatory agent which is prepared from 5, 5 '-diisopropyl-2, 2'-dimethyl biphenyl (3, 3 ', 4, 4', 1-ethyl piperidine, flavin mononucleotide, crystal orchid glycoside, 2-O-caffeoyl arbutin, dimethyl ellagic acid glucuronide, 4 '-hydroxy-3, 4, 5-resveratrol trimethyl ether, 3'-methoxy petamicin, phenylalanyl-leucyl-isoleucyl-tyrosine and dihydroferulic acid-4-sulfate.

The invention relates to a uridine diphosphate-glucuronyl transferase mutant and an application of the uridine diphosphate-glucuronyl transferase mutant in catalytic synthesis of glucuronide. The amino acid sequence of the uridine diphosphate-glucuronyl transferase mutant is as shown in SEQ ID NO. 2, and the nucleotide sequence of the coding gene is as shown in SEQ ID NO. 1. The invention provides a uridine diphosphate-glucuronyl transferase mutant with high activity and high stability. Compared with wild uridine diphosphate-glucuronyl transferase, the uridine diphosphate-glucuronyl transferase mutant has mutation of 10 amino acid sites. According to experimental determination, the melting temperature of the mutant is increased by 24 DEG C compared with that of a wild type, the activity is increased to 1.65 times, the expression quantity is increased to 4.2 times, and a powerful tool is provided for enzymatic synthesis of glucuronide compounds.

The invention provides a novel application of quercetin-3-O-beta-D-glucuronide, belongs to the technical field of medicines, and particularly relates to an application of the quercetin-3-O-beta-D-glucuronide in preparation of anti-aging medicines. According to the invention, quercetin-3-O-beta-D-glucuronide is extracted and separated from lotus leaves, and quercetin-3-O-beta-D-glucuronide can obviously prolong the service life of caenorhabditis elegans and has the effect of delaying senescence, so that quercetin-3-O-beta-D-glucuronide has the potential of delaying senescence, and can be used for preparing a medicine for treating caenorhabditis elegans. The traditional Chinese medicine composition can be applied to preparation of anti-aging medicines and also can be applied to preparation of health-care products for delaying aging.

The invention relates to the technical field of component detection of clerodendrum japonicum, in particular to a method for determining the content of active substances in clerodendrum japonicum based on a high performance liquid chromatography method. The invention provides a method for determining the content of active substances in clerodendrum japonicum based on high performance liquid chromatography, which comprises the following steps: (1) mixing the clerodendrum japonicum medicinal material with ethanol, and carrying out ultrasonic treatment to obtain a test solution; the method comprises the following steps: respectively taking a chlorogenic acid solution, an apigenin-7-O-diglucuronic acid solution, a verbascoside solution and an acacetin-7-O-[beta-D-glucopyranuronyl (1-> 2)-O-D-glucopyranuronide] solution as reference substance solutions; and (2) performing high performance liquid chromatography detection on the test solution and the reference solution obtained in the step (1). The method can be used for simultaneously detecting the contents of four active components in clerodendrum japonicum, is low in detection limit and wide in linear range, and ensures the accuracy and reliability of a detection result.

The invention belongs to the field of quantitative analysis of drug concentration of a cell lysis solution, and particularly discloses a method for detecting estradiol 17 beta-D glucuronic acid (Estradil 17-(beta-D-Glucuronide)) in the cell lysis solution. According to the method, the concentration of the estradiol 17 beta-D glucuronic acid in the cell lysis buffer can be accurately quantified through specific sample treatment and liquid chromatography and mass spectrometry conditions, the sensitivity is high, the detection limit is low, a novel method capable of being practically popularized and applied is provided for pharmacokinetic research of the estradiol 17 beta-D glucuronic acid, and the method has popularization and application values.

Compounds comprising a cross-linking moiety and a protecting group are described herein along with their methods of use. The cross-linking moiety may comprise an indoxyl and the protecting group may comprise a sugar (e.g., a glucuronide or glucoside), phosphoester, or sulfoester group. The cross-linking moiety and protecting group may be attached to each other via an oxygen atom, sulfur atom, or linker. In some embodiments, the linker attaching the cross-linking moiety and protecting group is a self-immolative linker. A compound of the present invention may cross-link under physiological conditions and / or in vivo.

The application discloses a kind of high-efficiency interception polyvalent anion and cation nanofiltration membrane and its preparation method and application.The method includes the following preparation process:1) preparation concentration is 0.1-2wt% of apigenin class of substance aqueous solution, and concentration is 0.1-0.5wt% of multi-acid chloride organic phase solution;2) make polymer support membrane in aqueous solution 1-5min, remove the surface excess solution, then immerse into oil phase solution, react 1-15min;3) after reaction, remove the surface excess solution, solidify 5-20min under 60-80 DEG C, obtain the nanofiltration membrane.The application is with apigenin, apigenin-7-o-glucuronide and / or isofraxidin as aqueous monomer, and multi-acid chloride is prepared by interfacial polymerization reaction to obtain negative NF membrane, not only maintain the high interception rate to polyvalent anion, and also have very high interception rate to polyvalent cation, can efficiently permeate monovalent ion, and water flux is larger.

This invention discloses an engineered bacterial strain for producing xylitol using glucose as the sole carbon source, its construction method, and its applications, belonging to the field of genetic engineering. Using *Escherichia coli* as the starting strain, this invention optimizes the metabolic pathway by knocking out the 2-keto-3-deoxy-6-phosphate glucuronide gene (eda), knocking out the 6-phosphoglucuronide dehydratase gene (edd), and weakening the glucose phosphoisomerase gene (pgi), thus concentrating the carbon flow in the pentose phosphate pathway. Furthermore, it optimizes the metabolic pathway by knocking out or overexpressing endogenous genes such as the ribulokinase gene (araB). Subsequently, the synthesis of xylitol from glucose was experimentally tested by expressing a recombinant expression plasmid containing 2-arabinol dehydrogenase, 4-arabinol dehydrogenase, and xylitol dehydrogenase. This invention, through optimized metabolic pathways, efficiently converts glucose to xylitol without the need for glycerol addition, and significantly increases the yields of both the precursor arabinol and the product xylitol, demonstrating promising production prospects.

A use of phenyl-β-D-glucuronide in preparation of a drug for induced exhalation detection of cancer. The phenyl-β-D-glucuronide is present in natural organisms, is verified to have no toxic or side ef

The invention discloses application of apigenin-7-O-glucuronide in preparation of a medicine for treating coronavirus, and belongs to the technical field of pharmacology of traditional Chinese medicines. The application comprises the application of the apigenin-7-O-glucuronide serving as the RIG-I protein agonist and the application of the apigenin-7-O-glucuronide in preparation of the medicine for treating the coronavirus. Experiments prove that the apigenin-7-O-glucuronide has a good inhibition effect on the coronavirus by being used as the RIG-I protein agonist, and an experimental basis is provided for the apigenin-7-O-glucuronide to prevent and treat the coronavirus infection.

The invention relates to a method for producing hyaluronic acid through cell-free catalysis, and belongs to the technical field of biological catalysis. According to the invention, a system capable of being applied to cell-free catalytic production of hyaluronic acid is constructed, and genetically engineered bacteria are used for expressing N-acetyl hexosamine 1-kinase, glucosamine-1-phosphate acetyl transferase, glucuronide kinase, GlcA-1-P uridinetransferase, hyaluronic acid synthase, polyphosphate kinase, uridine monophosphate kinase and inorganic pyrophosphatase; according to the present invention, N-acetylglucosamine GlcNAc, glucuronic acid GlcA, ATP and UMP are adopted as substrates to perform catalytic production, UDP and ADP produced during the reaction process are converted into ATP and UTP, such that nucleotide circulation is achieved, raw material consumption is reduced, the final hyaluronic acid yield reaches 1.28 g / L, and an economic and efficient brand new path is provided for hyaluronic acid industrial production.